Pathology

Daniel J. Diekema, MD

Portrait

Director, Division of Infectious Diseases
Clinical Professor of Internal Medicine  - Infectious Diseases
Clinical Professor of Pathology

Contact Information

Primary Office: SW54-15 GH
Iowa City, IA 52242
Primary Office Phone: 319-384-5626

Email: daniel-diekema@uiowa.edu

Education

BA, Calvin College, Grand Rapids, MI
MD, Vanderbilt University School of Medicine, Nashville, TN
MS, Preventive Medicine, University of Iowa College of Medicine, Iowa City, IA

Residency, Internal Medicine, University of Virginia, Charlottesville, VA
Fellowship, Infectious Diseases, The University of Iowa Hospitals and Clinics, Iowa City, IA
Fellowship, Clinical Microbiology, The University of Iowa Hospitals and Clinics, Iowa City, IA

Licensure and Certifications

Infectious Diseases, American Board of Internal Medicine
Internal Medicine, American Board of Internal Medicine

Research Summary

Interests: Several aspects of hospital epidemiology and clinical mycology, including the epidemiology of invasive fungal infections in hospitalized patients and the use of molecular typing in infection control and antimicrobial resistance control.

All Publications

Diekema D, Richter S, Hellmann K, Dohrn C, Riahi F, Tendolkar S, McDanel J, Doern G.  Continued Emergence of USA300 Methicillin-Resistant Staphylococcus aureus in the United States: Results from a Nationwide Surveillance Study.  Infection Control and Hospital Epidemiology.  2014 March. 35(3):285-92.
[PubMed]

Pfaller M, Neofytos D, Diekema D, Azie N, Meier-Kriesche H, Quan S, Horn D.  Epidemiology and outcomes of candidemia in 3648 patients: data from the Prospective Antifungal Therapy (PATH Alliance®) registry, 2004-2008..  Diagnostic microbiology and infectious disease.  2012 December. 74(4):323-31.
[PubMed]

Schweizer M, Graham M, Ohl M, Heilmann K, Boyken L, Diekema D.  Novel hospital curtains with antimicrobial properties: a randomized, controlled trial..  Infection control and hospital epidemiology : the official journal of the Society of Hospital Epidemiologists of America.  2012 November. 33(11):1081-5.
[PubMed]

Schweizer M, Ward M, Cobb S, McDanel J, Leder L, Wibbenmeyer L, Latenser B, Diekema D, Herwaldt L.  The epidemiology of methicillin-resistant Staphylococcus aureus on a burn trauma unit..  Infection control and hospital epidemiology : the official journal of the Society of Hospital Epidemiologists of America.  2012 November. 33(11):1118-25.
[PubMed]

Pfaller M, Diekema D, Andes D, Arendrup M, Brown S, Lockhart S, Motyl M, Perlin D.  Clinical breakpoints for the echinocandins and Candida revisited: integration of molecular, clinical, and microbiological data to arrive at species-specific interpretive criteria..  Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.  2011 June. 14(3):164-76.
[PubMed]

Chiang H, Steelman V, Pottinger J, Schlueter A, Diekema D, Greenlee J, Howard M, Herwaldt L.  Clinical significance of positive cranial bone flap cultures and associated risk of surgical site infection after craniotomies or craniectomies..  Journal of neurosurgery.  2011 June. 114(6):1746-54.
[PubMed]

Chaturvedi V, Ramani R, Andes D, Diekema D, Pfaller M, Ghannoum M, Knapp C, Lockhart S, Ostrosky-Zeichner L, Walsh T, Marchillo K, Messer S, Welshenbaugh A, Bastulli C, Iqbal N, Paetznick V, Rodriguez J, Sein T.  Multilaboratory testing of two-drug combinations of antifungals against Candida albicans, Candida glabrata, and Candida parapsilosis..  Antimicrobial agents and chemotherapy.  2011 April. 55(4):1543-8.
[PubMed]

Pfaller M, Boyken L, Hollis R, Kroeger J, Messer S, Tendolkar S, Diekema D.  Validation of 24-hour posaconazole and voriconazole MIC readings versus the CLSI 48-hour broth microdilution reference method: application of epidemiological cutoff values to results from a global Candida antifungal surveillance program..  Journal of clinical microbiology.  2011 April. 49(4):1274-9.
[PubMed]

Pfaller M, Espinel-Ingroff A, Boyken L, Hollis R, Kroeger J, Messer S, Tendolkar S, Diekema D.  Comparison of the broth microdilution (BMD) method of the European Committee on Antimicrobial Susceptibility Testing with the 24-hour CLSI BMD method for testing susceptibility of Candida species to fluconazole, posaconazole, and voriconazole by use of epidemiological cutoff values..  Journal of clinical microbiology.  2011 March. 49(3):845-50.
[PubMed]

Pfaller M, Boyken L, Hollis R, Kroeger J, Messer S, Tendolkar S, Diekema D.  Wild-type MIC distributions and epidemiological cutoff values for posaconazole and voriconazole and Candida spp. as determined by 24-hour CLSI broth microdilution..  Journal of clinical microbiology.  2011 February. 49(2):630-7.
[PubMed]

Kroeger J, Diekema D, Quan V, Kim D, Peterson E, Evans K, Tan G, Hayden M, Huang S.  Chlorhexidine and Mupirocin Susceptibility of Methicillin-Resistant Staphylococcus aureus from Long-Term Care Facility Patients.  2011. 

Herwaldt L, Ward M, Cobb S, Leder L, Kroeger J, Diekema D.  The Epidemiology of Methicillin-Resistant S. aureus on a Burn-Trauma Unit.  2011. 

Leedom Larson K, Harper A, Hanson B, Male M, Wardyn S, Dressler A, Wagstrom E, Tendolkar S, Diekema D, Donham K, Smith T.  Methicillin-resistant Staphylococcus aureus in pork production shower facilities..  Applied and environmental microbiology.  2011 January. 77(2):696-8.
[PubMed]

Pfaller M, Andes D, Diekema D, Espinel-Ingroff A, Sheehan D.  Wild-type MIC distributions, epidemiological cutoff values and species-specific clinical breakpoints for fluconazole and Candida: time for harmonization of CLSI and EUCAST broth microdilution methods..  Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.  2010 December. 13(6):180-95.
[PubMed]

Espinel-Ingroff A, Diekema D, Fothergill A, Johnson E, Pelaez T, Pfaller M, Rinaldi M, Canton E, Turnidge J.  Wild-type MIC distributions and epidemiological cutoff values for the triazoles and six Aspergillus spp. for the CLSI broth microdilution method (M38-A2 document)..  Journal of clinical microbiology.  2010 September. 48(9):3251-7.
[PubMed]

Perencevich E, Diekema D.  Decline in invasive MRSA infection: where to go from here?.  JAMA : the journal of the American Medical Association.  2010 August. 304(6):687-9.
[PubMed]

Pfaller M, Diekema D, Gibbs D, Newell V, Barton R, Bijie H, Bille J, Chang S, da Luz Martins M, Duse A, Dzierzanowska D, Ellis D, Finquelievich J, Gould I, Gur D, Hoosen A, Lee K, Mallatova N, Mallie M, Peng N, Petrikos G, Santiago A, Trupl J, VanDen Abeele A, Wadula J, Zaidi M.  Geographic variation in the frequency of isolation and fluconazole and voriconazole susceptibilities of Candida glabrata: an assessment from the ARTEMIS DISK Global Antifungal Surveillance Program..  Diagnostic microbiology and infectious disease.  2010 June. 67(2):162-71.
[PubMed]

Andes D, Diekema D, Pfaller M, Bohrmuller J, Marchillo K, Lepak A.  In vivo comparison of the pharmacodynamic targets for echinocandin drugs against Candida species..  Antimicrobial agents and chemotherapy.  2010 June. 54(6):2497-506.
[PubMed]

Castanheira M, Woosley L, Diekema D, Messer S, Jones R, Pfaller M.  Low prevalence of fks1 hot spot 1 mutations in a worldwide collection of Candida strains..  Antimicrobial agents and chemotherapy.  2010 June. 54(6):2655-9.
[PubMed]

Pfaller M, Castanheira M, Diekema D, Messer S, Moet G, Jones R.  Comparison of European Committee on Antimicrobial Susceptibility Testing (EUCAST) and Etest methods with the CLSI broth microdilution method for echinocandin susceptibility testing of Candida species..  Journal of clinical microbiology.  2010 May. 48(5):1592-9.
[PubMed]

Polgreen P, Beekmann S, Diekema D, Sherertz R.  Wide variability in the use of antimicrobial lock therapy and prophylaxis among infectious diseases consultants..  Infection control and hospital epidemiology : the official journal of the Society of Hospital Epidemiologists of America.  2010 May. 31(5):554-7.
[PubMed]

Pfaller M, Boyken L, Hollis R, Kroeger J, Messer S, Tendolkar S, Diekema D.  Wild-type minimum effective concentration distributions and epidemiologic cutoff values for caspofungin and Aspergillus spp. as determined by Clinical and Laboratory Standards Institute broth microdilution methods..  Diagnostic microbiology and infectious disease.  2010 May. 67(1):56-60.
[PubMed]

Pfaller M, Diekema D, Gibbs D, Newell V, Ellis D, Tullio V, Rodloff A, Fu W, Ling T.  Results from the ARTEMIS DISK Global Antifungal Surveillance Study, 1997 to 2007: a 10.5-year analysis of susceptibilities of Candida Species to fluconazole and voriconazole as determined by CLSI standardized disk diffusion..  Journal of clinical microbiology.  2010 April. 48(4):1366-77.
[PubMed]

Peterson L, Diekema D.  To screen or not to screen for methicillin-resistant Staphylococcus aureus..  Journal of clinical microbiology.  2010 March. 48(3):683-9.
[PubMed]

Richter S, Heilmann K, Dohrn C, Riahi F, Costello A, Kroeger J, Diekema D, Doern G.  Activity of ceftaroline against 4210 Staphylococcus aureus isolates from 43 United States centers, 2009.  2010. 

Andrews J, Coffin J, Fleener D, Diekema D.  Association of Toll Like receptor 2 (TLR2) genetic polymorphisms with Staphylococcus aureus colonization during pregnancy.  2010. 

Pfaller M, Diekema D, Andes D, Arendrup M, Brown S, Motyl M, Perlin D.  Clinical breakpoints for the echinocandins and Candida, revisited.  2010. 

Pfaller M, Boyken L, Hollis R, Messer S, Tendolkar S, Diekema D.  Comparison of broth microdilution methods of EUCAST and CLSI for testing fluconazole, posaconazole and voriconazole against Candida spp.  2010. 

Diekema D, Boyken L, Hollis R, Kroeger J, Messer S, Tendolkar S, Pfaller M.  Comparison of the broth microdilution methods of EUCAST and the CLSI for testing itraconazole, posaconazole and voriconazole against Aspergillus species.  2010. 

Pfaller M, Diekema D.  Epidemiology of invasive mycoses in North America..  Critical reviews in microbiology.  2010. 36(1):1-53.
[PubMed]

Richter S, Heilmann K, Dohrn C, Kroeger J, Diekema D, Doern G.  Epidemiology of methicillin-resistant Staphylococcus aureus (MRSA) in the United States, 2009.  2010. 

Mendes R, Smith T, Deshpande L, Diekema D, Sader H, Jones R.  Plasmid borne vga(A)-encoding gene in methicillin-resistant Staphylococcus aureus (MRSA) ST-398 from swine and swine farmers in the United States.  2010. 

Pfaller M, Boyken L, Hollis R, Kroeger J, Messer S, Tendolkar S, Diekema D.  Use of epidemiologic cutoff values (ECVs) to examine 9-year trends in susceptibility of Aspergillus species to the triazoles.  2010. 

Diekema D, Pfaller M.  Utility of Antifungal Susceptibility Testing and Clinical Correlations.  2010. 

Pfaller M, Boyken L, Hollis R, Kroeger J, Messer S, Tendolkar S, Jones R, Turnidge J, Diekema D.  Wild-type MIC distributions and epidemiological cutoff values for the echinocandins and Candida spp..  Journal of clinical microbiology.  2010 January. 48(1):52-6.
[PubMed]

Pfaller M, Messer S, Georgopapadakou N, Martell L, Besterman J, Diekema D.  Activity of MGCD290, a Hos2 histone deacetylase inhibitor, in combination with azole antifungals against opportunistic fungal pathogens..  Journal of clinical microbiology.  2009 December. 47(12):3797-804.
[PubMed]

Siikala E, Richardson M, Pfaller M, Diekema D, Messer S, Perheentupa J, Saxén H, Rautemaa R.  Candida albicans isolates from APECED patients show decreased susceptibility to miconazole..  International journal of antimicrobial agents.  2009 December. 34(6):607-9.
[PubMed]

Etienne K, Gade L, Lockhart S, Diekema D, Messer S, Pfaller M, Balajee S.  Screening of a large global Aspergillus fumigatus species complex collection by using a species-specific microsphere-based Luminex assay..  Journal of clinical microbiology.  2009 December. 47(12):4171-2.
[PubMed]

Van De Griend P, Herwaldt L, Alvis B, DeMartino M, Heilmann K, Doern G, Winokur P, Vonstein D, Diekema D.  Community-associated methicillin-resistant Staphylococcus aureus, Iowa, USA..  Emerging infectious diseases.  2009 October. 15(10):1582-9.
[PubMed]

Diekema D, Messer S, Boyken L, Hollis R, Kroeger J, Tendolkar S, Pfaller M.  In vitro activity of seven systemically active antifungal agents against a large global collection of rare Candida species as determined by CLSI broth microdilution methods..  Journal of clinical microbiology.  2009 October. 47(10):3170-7.
[PubMed]

Pfaller M, Boyken L, Hollis R, Kroeger J, Messer S, Tendolkar S, Diekema D.  In vitro susceptibility of clinical isolates of Aspergillus spp. to anidulafungin, caspofungin, and micafungin: a head-to-head comparison using the CLSI M38-A2 broth microdilution method..  Journal of clinical microbiology.  2009 October. 47(10):3323-5.
[PubMed]

Andrews J, Fleener D, Messer S, Kroeger J, Diekema D.  Screening for Staphylococcus aureus carriage in pregnancy: usefulness of novel sampling and culture strategies..  American journal of obstetrics and gynecology.  2009 October. 201(4):396.e1-5.
[PubMed]

Pfaller M, Messer S, Hollis R, Boyken L, Tendolkar S, Kroeger J, Diekema D.  Variation in susceptibility of bloodstream isolates of Candida glabrata to fluconazole according to patient age and geographic location in the United States in 2001 to 2007..  Journal of clinical microbiology.  2009 October. 47(10):3185-90.
[PubMed]

Pfaller M, Diekema D, Ghannoum M, Rex J, Alexander B, Andes D, Brown S, Chaturvedi V, Espinel-Ingroff A, Fowler C, Johnson E, Knapp C, Motyl M, Ostrosky-Zeichner L, Sheehan D, Walsh T.  Wild-type MIC distribution and epidemiological cutoff values for Aspergillus fumigatus and three triazoles as determined by the Clinical and Laboratory Standards Institute broth microdilution methods..  Journal of clinical microbiology.  2009 October. 47(10):3142-6.
[PubMed]

Pfaller M, Boyken L, Hollis R, Kroeger J, Messer S, Tendolkar S, Diekema D.  Comparison of results of fluconazole and voriconazole disk diffusion testing for Candida spp. with results from a central reference laboratory in the ARTEMIS DISK Global Antifungal Surveillance Program..  Diagnostic microbiology and infectious disease.  2009 September. 65(1):27-34.
[PubMed]

Reighard A, Diekema D, Wibbenmeyer L, Ward M, Herwaldt L.  Staphylococcus aureus nasal colonization and colonization or infection at other body sites in patients on a burn trauma unit..  Infection control and hospital epidemiology : the official journal of the Society of Hospital Epidemiologists of America.  2009 August. 30(8):721-6.
[PubMed]

Klevay M, Horn D, Neofytos D, Pfaller M, Diekema D.  Initial treatment and outcome of Candida glabrata versus Candida albicans bloodstream infection..  Diagnostic microbiology and infectious disease.  2009 June. 64(2):152-7.
[PubMed]

Lockhart S, Messer S, Gherna M, Bishop J, Merz W, Pfaller M, Diekema D.  Identification of Candida nivariensis and Candida bracarensis in a large global collection of Candida glabrata isolates: comparison to the literature..  Journal of clinical microbiology.  2009 April. 47(4):1216-7.
[PubMed]

Morgan D, Diekema D, Sepkowitz K, Perencevich E.  Adverse outcomes associated with Contact Precautions: a review of the literature..  American journal of infection control.  2009 March. 37(2):85-93.
[PubMed]

Endimiani A, Hujer A, Perez F, Bethel C, Hujer K, Kroeger J, Oethinger M, Paterson D, Adams M, Jacobs M, Diekema D, Hall G, Jenkins S, Rice L, Tenover F, Bonomo R.  Characterization of blaKPC-containing Klebsiella pneumoniae isolates detected in different institutions in the Eastern USA..  The Journal of antimicrobial chemotherapy.  2009 March. 63(3):427-37.
[PubMed]

Diekema D, Messer S, Hollis R, Boyken L, Tendolkar S, Kroeger J, Jones R, Pfaller M.  A global evaluation of voriconazole activity tested against recent clinical isolates of Candida spp..  Diagnostic microbiology and infectious disease.  2009 February. 63(2):233-6.
[PubMed]

Pottinger J, Steelman V, Schlueter A, Chiang H, Diekema D, Herwaldt L.  Clinical significance of positive cranial bone flap cultures, and risk of surgical site infection post-craniotomy.  2009. 

Wyatt C, Winokur P, Page J, Von Stein D, Diekema D.  Differing acquisition rates of MRSA and VRE during an active surveillance-contact precautions intervention.  2009. 

Smith T, Male M, Harper A, Kroeger J, Tinkler G, Moritz E, Capuano A, Herwaldt L, Diekema D.  Methicillin-resistant Staphylococcus aureus (MRSA) strain ST398 is present in midwestern U.S. swine and swine workers..  PloS one.  2009. 4(1):e4258.
[PubMed]

Lockhart S, Messer S, Pfaller M, Diekema D.  Identification and Susceptibility Profile of Candida fermentati from a worldwide collection of Candida guilliermondii clinical isolates..  Journal of clinical microbiology.  2009 January. 47(1):242-4.
[PubMed]

Pfaller M, Diekema D, Gibbs D, Newell V, Bijie H, Dzierzanowska D, Klimko N, Letscher-Bru V, Lisalova M, Muehlethaler K, Rennison C, Zaidi M.  Results from the ARTEMIS DISK Global Antifungal Surveillance Study, 1997 to 2007: 10.5-year analysis of susceptibilities of noncandidal yeast species to fluconazole and voriconazole determined by CLSI standardized disk diffusion testing..  Journal of clinical microbiology.  2009 January. 47(1):117-23.
[PubMed]

Ostrosky-Zeichner L, Rex J, Pfaller M, Diekema D, Alexander B, Andes D, Brown S, Chaturvedi V, Ghannoum M, Knapp C, Sheehan D, Walsh T.  Rationale for reading fluconazole MICs at 24 hours rather than 48 hours when testing Candida spp. by the CLSI M27-A2 standard method..  Antimicrobial agents and chemotherapy.  2008 November. 52(11):4175-7.
[PubMed]

Riedel S, Von Stein D, Richardson K, Page J, Miller S, Winokur P, Diekema D.  Development of a prediction rule for methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococcus carriage in a Veterans Affairs Medical Center population..  Infection control and hospital epidemiology : the official journal of the Society of Hospital Epidemiologists of America.  2008 October. 29(10):969-71.
[PubMed]

Andes D, Diekema D, Pfaller M, Marchillo K, Bohrmueller J.  In vivo pharmacodynamic target investigation for micafungin against Candida albicans and C. glabrata in a neutropenic murine candidiasis model..  Antimicrobial agents and chemotherapy.  2008 October. 52(10):3497-503.
[PubMed]

Andrews J, Shamshirsaz A, Diekema D.  Nonmenstrual toxic shock syndrome due to methicillin-resistant Staphylococcus aureus..  Obstetrics and gynecology.  2008 October. 112(4):933-8.
[PubMed]

Wrobel L, Whittington J, Pujol C, Oh S, Ruiz M, Pfaller M, Diekema D, Soll D, Hoyer L.  Molecular phylogenetic analysis of a geographically and temporally matched set of Candida albicans isolates from humans and nonmigratory wildlife in central Illinois..  Eukaryotic cell.  2008 September. 7(9):1475-86.
[PubMed]

Pfaller M, Diekema D, Ostrosky-Zeichner L, Rex J, Alexander B, Andes D, Brown S, Chaturvedi V, Ghannoum M, Knapp C, Sheehan D, Walsh T.  Correlation of MIC with outcome for Candida species tested against caspofungin, anidulafungin, and micafungin: analysis and proposal for interpretive MIC breakpoints..  Journal of clinical microbiology.  2008 August. 46(8):2620-9.
[PubMed]

Lockhart S, Messer S, Pfaller M, Diekema D.  Geographic distribution and antifungal susceptibility of the newly described species Candida orthopsilosis and Candida metapsilosis in comparison to the closely related species Candida parapsilosis..  Journal of clinical microbiology.  2008 August. 46(8):2659-64.
[PubMed]

Pfaller M, Messer S, Boyken L, Rice C, Tendolkar S, Hollis R, Diekema D.  In vitro survey of triazole cross-resistance among more than 700 clinical isolates of Aspergillus species..  Journal of clinical microbiology.  2008 August. 46(8):2568-72.
[PubMed]

Diekema D.  Benefits and drawbacks of universal surveillance of methicillin-resistant Staphylococcus aureus..  Annals of internal medicine.  2008 July. 149(1):67; author reply 68-9.
[PubMed]

Pfaller M, Chaturvedi V, Diekema D, Ghannoum M, Holliday N, Killian S, Knapp C, Messer S, Miskov A, Ramani R.  Clinical evaluation of the Sensititre YeastOne colorimetric antifungal panel for antifungal susceptibility testing of the echinocandins anidulafungin, caspofungin, and micafungin..  Journal of clinical microbiology.  2008 July. 46(7):2155-9.
[PubMed]

Huang S, Diekema D, Warren D, Zuccotti G, Winokur P, Tendolkar S, Boyken L, Datta R, Jones R, Ward M, Aubrey T, Onderdonk A, Garcia C, Platt R.  Strain-relatedness of methicillin-resistant Staphylococcus aureus isolates recovered from patients with repeated infection..  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.  2008 April. 46(8):1241-7.
[PubMed]

Pfaller M, Diekema D, Gibbs D, Newell V, Ng K, Colombo A, Finquelievich J, Barnes R, Wadula J.  Geographic and temporal trends in isolation and antifungal susceptibility of Candida parapsilosis: a global assessment from the ARTEMIS DISK Antifungal Surveillance Program, 2001 to 2005..  Journal of clinical microbiology.  2008 March. 46(3):842-9.
[PubMed]

Diekema D, Climo M.  Preventing MRSA infections: finding it is not enough..  JAMA : the journal of the American Medical Association.  2008 March. 299(10):1190-2.
[PubMed]

Klevay M, Ernst E, Hollanbaugh J, Miller J, Pfaller M, Diekema D.  Therapy and outcome of Candida glabrata versus Candida albicans bloodstream infection..  Diagnostic microbiology and infectious disease.  2008 March. 60(3):273-7.
[PubMed]

Pfaller M, Diekema D, Gibbs D, Newell V, Nagy E, Dobiasova S, Rinaldi M, Barton R, Veselov A.  Candida krusei, a multidrug-resistant opportunistic fungal pathogen: geographic and temporal trends from the ARTEMIS DISK Antifungal Surveillance Program, 2001 to 2005..  Journal of clinical microbiology.  2008 February. 46(2):515-21.
[PubMed]

Andes D, Diekema D, Pfaller M, Prince R, Marchillo K, Ashbeck J, Hou J.  In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model..  Antimicrobial agents and chemotherapy.  2008 February. 52(2):539-50.
[PubMed]

Pfaller M, Messer S, Boyken L, Tendolkar S, Hollis R, Diekema D.  Selection of a surrogate agent (fluconazole or voriconazole) for initial susceptibility testing of posaconazole against Candida spp.: results from a global antifungal surveillance program..  Journal of clinical microbiology.  2008 February. 46(2):551-9.
[PubMed]

Klevay M, Coffman S, David S, Lockhart S, Latenser B, Heile J, Herwaldt L, Diekema D.  A cluster of Aspergillus flavus wound infections in a burn unit.  2008. 

Diekema D, Messer S, Hollis R, Kroeger J, Boyken L, Tendolkar S, Pfaller M.  Antifungal Activity Against a Large Global Collection of Rare Candida Species.  2008. 

Polgreen P, Beekmann S, Diekema D, Sherertz R.  Antimicrobial lock therapy and prophylaxis practice patterns: An Emerging Infections Network Survey.  2008. 

Diekema D, Messer S, Besterman J, Pfaller M.  Combination Testing of MGCD290, a Fungal Histone Deacetylase Inhibitor, with Azole Antifungals against a Large Collection of Clinical Fungal Isolates.  2008. 

Wibbenmeyer L, Kealey G, Latenser B, Diekema D, Williams I, Coffman S, Winokur P, Kroeger J, Lewis R, Herwaldt L.  Emergence of the USA300 strain of methicillin-resistant Staphylococcus aureus in a burn-trauma unit..  Journal of burn care & research : official publication of the American Burn Association.  2008. 29(5):790-7.
[PubMed]

Klevay M, Horn D, Neofytos D, Pfaller M, Diekema D.  Empiric Treatment and Outcome of Candida glabrata versus C. albicans Bloodstream Infection.  2008. 

Pfaller M, Diekema D, Merz W.  Infections caused by non-Candida, non-Cryptococcis yeasts.  2008. 

Pfaller M, Messer S, Kroeger J, Boyken L, Tendolkar S, Hollis R, Diekema D.  Reading Fluconazole Susceptibility after 24 Hours: Validation against the Clinical and Laboratory Standards Institute (CLSI) Reference Methods.  2008. 

Klevay M, Diekema D.  Response to letter to the editor.  Diagn Microbiol Infect Dis.  2008. 61:364.

Reighard A, Diekema D, Wibbenmeyer L, Ward M, Herwaldt L.  Staphylococcus aureus colonization and infection on a burn/trauma unit.  2008. 

Lockhart S, Diekema D, Pfaller M.  The epidemiology of fungal infections.  2008. 

Diekema D, Messer S, Hollis R, Kroeger J, Boyken L, Tendolkar S, Lockhart S, Jones R, Pfaller M.  Voriconazole Activity Against Aspergillus spp: Eight Years of Global Surveillance.  2008. 

Pfaller M, Boyken L, Hollis R, Kroeger J, Messer S, Tendolkar S, Diekema D.  In vitro susceptibility of invasive isolates of Candida spp. to anidulafungin, caspofungin, and micafungin: six years of global surveillance..  Journal of clinical microbiology.  2008 January. 46(1):150-6.
[PubMed]

Lockhart S, Messer S, Pfaller M, Diekema D.  Lodderomyces elongisporus masquerading as Candida parapsilosis as a cause of bloodstream infections..  Journal of clinical microbiology.  2008 January. 46(1):374-6.
[PubMed]

Zhao X, Oh S, Jajko R, Diekema D, Pfaller M, Pujol C, Soll D, Hoyer L.  Analysis of ALS5 and ALS6 allelic variability in a geographically diverse collection of Candida albicans isolates..  Fungal genetics and biology : FG & B.  2007 December. 44(12):1298-309.
[PubMed]

Pfaller M, Diekema D, Procop G, Rinaldi M.  Multicenter comparison of the VITEK 2 antifungal susceptibility test with the CLSI broth microdilution reference method for testing amphotericin B, flucytosine, and voriconazole against Candida spp..  Journal of clinical microbiology.  2007 November. 45(11):3522-8.
[PubMed]

Lockhart S, Abramson M, Beekmann S, Gallagher G, Riedel S, Diekema D, Quinn J, Doern G.  Antimicrobial resistance among Gram-negative bacilli causing infections in intensive care unit patients in the United States between 1993 and 2004..  Journal of clinical microbiology.  2007 October. 45(10):3352-9.
[PubMed]

Andrews J, Fleener D, Messer S, Hansen W, Pfaller M, Diekema D.  The yeast connection: is Candida linked to breastfeeding associated pain?.  American journal of obstetrics and gynecology.  2007 October. 197(4):424.e1-4.
[PubMed]

Flanagan M, Ramanujam R, Sutherland J, Vaughn T, Diekema D, Doebbeling B.  Development and validation of measures to assess prevention and control of AMR in hospitals..  Medical care.  2007 June. 45(6):537-44.
[PubMed]

Diekema D, Messer S, Hollis R, Boyken L, Tendolkar S, Kroeger J, Pfaller M.  Evaluation of Etest and disk diffusion methods compared with broth microdilution antifungal susceptibility testing of clinical isolates of Candida spp. against posaconazole..  Journal of clinical microbiology.  2007 June. 45(6):1974-7.
[PubMed]

Pfaller M, Diekema D, Gibbs D, Newell V, Meis J, Gould I, Fu W, Colombo A, Rodriguez-Noriega E.  Results from the ARTEMIS DISK Global Antifungal Surveillance study, 1997 to 2005: an 8.5-year analysis of susceptibilities of Candida species and other yeast species to fluconazole and voriconazole determined by CLSI standardized disk diffusion testing..  Journal of clinical microbiology.  2007 June. 45(6):1735-45.
[PubMed]

Messer S, Diekema D, Hollis R, Boyken L, Tendolkar S, Kroeger J, Pfaller M.  Evaluation of disk diffusion and Etest compared to broth microdilution for antifungal susceptibility testing of posaconazole against clinical isolates of filamentous fungi..  Journal of clinical microbiology.  2007 April. 45(4):1322-4.
[PubMed]

Diekema D, Edmond M.  Look before you leap: active surveillance for multidrug-resistant organisms..  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.  2007 April. 44(8):1101-7.
[PubMed]

Pfaller M, Diekema D, Procop G, Rinaldi M.  Multicenter comparison of the VITEK 2 yeast susceptibility test with the CLSI broth microdilution reference method for testing fluconazole against Candida spp..  Journal of clinical microbiology.  2007 March. 45(3):796-802.
[PubMed]

Polgreen P, Chen Y, Cavanaugh J, Ward M, Coffman S, Hornick D, Diekema D, Herwaldt L.  An outbreak of severe Clostridium difficile-associated disease possibly related to inappropriate antimicrobial therapy for community-acquired pneumonia..  Infection control and hospital epidemiology : the official journal of the Society of Hospital Epidemiologists of America.  2007 February. 28(2):212-4.
[PubMed]

Diekema D.  Healthcare-associated fungal infections: beyond Candida and Aspergillus..  Southern medical journal.  2007 February. 100(2):130-1.
[PubMed]

Huang S, Rifas-Shiman S, Warren D, Fraser V, Climo M, Wong E, Cosgrove S, Perl T, Pottinger J, Herwaldt L, Jernigan J, Tokars J, Diekema D, Hinrichsen V, Yokoe D, Platt R.  Improving methicillin-resistant Staphylococcus aureus surveillance and reporting in intensive care units..  The Journal of infectious diseases.  2007 February. 195(3):330-8.
[PubMed]

Huang S, Rifas-Shiman S, Pottinger J, Herwaldt L, Zembower T, Noskin G, Cosgrove S, Perl T, Curtis A, Tokars J, Diekema D, Jernigan J, Hinrichsen V, Yokoe D, Platt R.  Improving the assessment of vancomycin-resistant enterococci by routine screening..  The Journal of infectious diseases.  2007 February. 195(3):339-46.
[PubMed]

Von Stein D, Diekema D, Richardson K, Page J, Riedel S, Miller S, Winokur P.  "Real-life" performance of real-time PCR for detection of MRSA and VRE.  2007. 

Hollanbaugh J, Ernst E, Klevay M, Ngo N, Miller J, Pfaller M, Diekema D.  A case-case-control study of antimicrobial use and other risk factors for candidemia.  2007. 

Song X, Yokoe D, Platt R, Herwaldt L, Diekema D, Zuccotti G, Plaskett T, Wong E, Climo M, Cosgrove S, Perl T.  A multi-site assessment of an antimicrobial and diagnosis code-based screening tool to detect surgical site infections following craniotomy.  2007. 

Knapp C, Holliday N, Miskov A, Killian S, Ghannoum M, Pfaller M, Messer S, Diekema D, Chaturvedi V.  A multi-site evaluation of two new echinocandins anidulafungin, and micafungin on a colorimetric MIC susceptibility test plate compared with the CLSI M27 reference broth microdilution (BMD) plate for antifungal susceptibility testing.  2007. 

Pfaller M, Diekema D, Andes D, Rinaldi M, Fothergill A, Pappas P, Lortholary O, Mohr J, Kovanda L, Villmann M, Buell D.  A proposal for an antifungal susceptibility testing breakpoint for micafungin and Candida: Integration of AST surveys and correlation with clinical outcomes.  2007. 

Piehl D, Diekema D, Howard W, Andrews J.  Absence of vaginal methicillin-resistant Staphylococcus aureus (MRSA) carriage in the setting of increasing community associated MRSA rates.  2007. 

Pfaller M, Diekema D.  Azole antifungal drug cross-resistance: Resistance mechanisms, epidemiology, and clinical significance.  J Invasive Fungal Infect.  2007. 1:74-62.

Pfaller M, Diekema D, Gibbs D, Newell V, Nagy E, Dobiasova S, Rinaldi M, Barton R, Veselov A.  Candida krusei, a multidrug-resistant fungal pathogen: Geographical and temporal trends form the ARTEMIS DISK Antifungal Surveillance Program.  2007. 

Van de Griend P, Herwaldt L, Alvis B, Demartino M, Heilmann K, Doern G, Winokur P, Diekema D.  Community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA): An emerging cause of bloodstream infection (BSI) in Iowa.  2007. 

Alamu J, Diekema D, Davis P, Herwaldt L.  Evaluation of antimicrobial use in a pediatric intensive care unit (PICU).  2007. 

Pfaller M, Diekema D, Gibbs D, Newell V, Ng K, Colombo A, Finquelievich J, Barnes R, Wadula J.  Geographic and temporal trends in the isolation and antifungal susceptibility of Candida parapsilosis: A global assessment from the ARTEMIS DISK Antifungal Surveillance Program.  2007. 

Lockhart S, Messer S, Tendolkar S, Pfaller M, Diekema D.  Geographic distribution and antifungal susceptibility of the newly described species Candida orthopsilosis, in comparison to the closely-related species Candida parapsilosis.  2007. 

Riedel S, Von Stein D, Miller S, Page J, Winokur P, Diekema D.  Identifying MRSA or VRE carriers in a Veterans Affairs Medical Center population.  2007. 

Pfaller M, Boyken L, Hollis R, Kroeger J, Messer S, Tendolkar S, Diekema D.  In vitro susceptibility of Candida spp. to anidulafungin, caspofungin, and micafungin: Six years of global surveillance.  2007. 

Johannsson B, Chen Y, Beekmann S, Shamsuddin H, Diekema D, Herwaldt L, Polgreen P.  Methicillin susceptible Staphylococcus aureus bloodstream infection: Missed opportunities to optimize antimicrobial therapy.  2007. 

Pfaller M, Diekema D, Procop G, Rinaldi M.  Multicenter comparison of the VITEK 2 Yeast Susceptibility Test with the CLSI broth microdilution method for testing amphotericin B, flucytosine, and voriconazole against Candida spp.  2007. 

Diekema D, Messer S, Hollis R, Boyken L, Tendolkar S, Kroeger J, Pfaller M.  Patterns of cross-resistance/susceptibility among a large collection of clinical isolates of Aspergillus spp.  2007. 

Pfaller M, Messer S, Boyken L, Tendolkar S, Kroeger J, Diekema D.  Selection of a surrogate agent (fluconazole or voriconazole) for initial susceptibility testing of posaconazole against Candida: Results from a global antifungal surveillance program.  2007. 

Diekema D, Messer S, Georgopapdakou N, Pfaller M.  Synergy of MG3290, a histone deacetylase inhibitor, with azoles tested against clinical isolates of Candida and Aspergillus.  2007. 

Klevay M, Ernst E, Hollanbaugh J, Miller J, Pfaller M, Diekema D.  The epidemiology and impact of untreated candidemia.  2007. 

Patel S, Diekema D, Leung J, Applegate D, Winokur P, Von Stein D, Boyken L, Kroeger J, Herwaldt L.  The epidemiology of MRSA at a university hospital in a rural state.  2007. 

Klevay M, Ernst E, Miller J, Hollanbaugh J, Pfaller M, Diekema D.  The importance of appropriate therapy for candidemia.  2007. 

Andrews J, Fleener D, Diekema D.  The Yeast Connection – is Candida linked to breastfeeding associated pain?.  2007. 

Pfaller M, Diekema D.  Epidemiology of invasive candidiasis: a persistent public health problem..  Clinical microbiology reviews.  2007 January. 20(1):133-63.
[PubMed]

Pfaller M, Messer S, Boyken L, Rice C, Tendolkar S, Hollis R, Diekema D.  Use of fluconazole as a surrogate marker to predict susceptibility and resistance to voriconazole among 13,338 clinical isolates of Candida spp. Tested by clinical and laboratory standards institute-recommended broth microdilution methods..  Journal of clinical microbiology.  2007 January. 45(1):70-5.
[PubMed]

Neofytos D, Pfaller M, Diekema D, Horn D.  A case of recurrent episodes of Candida parapsilosis fungemia..  Mycopathologia.  2006 October. 162(4):295-8.
[PubMed]

Zillich A, Sutherland J, Wilson S, Diekema D, Ernst E, Vaughn T, Doebbeling B.  Antimicrobial use control measures to prevent and control antimicrobial resistance in US hospitals..  Infection control and hospital epidemiology : the official journal of the Society of Hospital Epidemiologists of America.  2006 October. 27(10):1088-95.
[PubMed]

Pfaller M, Diekema D, Mendez M, Kibbler C, Erzsebet P, Chang S, Gibbs D, Newell V.  Candida guilliermondii, an opportunistic fungal pathogen with decreased susceptibility to fluconazole: geographic and temporal trends from the ARTEMIS DISK antifungal surveillance program..  Journal of clinical microbiology.  2006 October. 44(10):3551-6.
[PubMed]

Pfaller M, Diekema D, Colombo A, Kibbler C, Ng K, Gibbs D, Newell V.  Candida rugosa, an emerging fungal pathogen with resistance to azoles: geographic and temporal trends from the ARTEMIS DISK antifungal surveillance program..  Journal of clinical microbiology.  2006 October. 44(10):3578-82.
[PubMed]

Pfaller M, Boyken L, Hollis R, Messer S, Tendolkar S, Diekema D.  Global surveillance of in vitro activity of micafungin against Candida: a comparison with caspofungin by CLSI-recommended methods..  Journal of clinical microbiology.  2006 October. 44(10):3533-8.
[PubMed]

Sigurdardottir B, Berg J, Hu J, Alamu J, McNutt L, Diekema D, Herwaldt L.  Descriptive epidemiology and case-control study of patients colonized with vancomycin-resistant enterococcus and methicillin-resistant Staphylococcus aureus..  Infection control and hospital epidemiology : the official journal of the Society of Hospital Epidemiologists of America.  2006 September. 27(9):913-9.
[PubMed]

Warren D, Cosgrove S, Diekema D, Zuccotti G, Climo M, Bolon M, Tokars J, Noskin G, Wong E, Sepkowitz K, Herwaldt L, Perl T, Solomon S, Fraser V.  A multicenter intervention to prevent catheter-associated bloodstream infections..  Infection control and hospital epidemiology : the official journal of the Society of Hospital Epidemiologists of America.  2006 July. 27(7):662-9.
[PubMed]

Siwek G, Pfaller M, Polgreen P, Cobb S, Hoth P, Magalheas-Silverman M, Diekema D.  Incidence of invasive aspergillosis among allogeneic hematopoietic stem cell transplant patients receiving voriconazole prophylaxis..  Diagnostic microbiology and infectious disease.  2006 July. 55(3):209-12.
[PubMed]

Beekmann S, Diekema D, Heilmann K, Richter S, Doern G.  Macrolide use identified as risk factor for macrolide-resistant Streptococcus pneumoniae in a 17-center case-control study..  European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology.  2006 May. 25(5):335-9.
[PubMed]

Pfaller M, Diekema D, Sheehan D.  Interpretive breakpoints for fluconazole and Candida revisited: a blueprint for the future of antifungal susceptibility testing..  Clinical microbiology reviews.  2006 April. 19(2):435-47.
[PubMed]

Pfaller M, Diekema D, Rex J, Espinel-Ingroff A, Johnson E, Andes D, Chaturvedi V, Ghannoum M, Odds F, Rinaldi M, Sheehan D, Troke P, Walsh T, Warnock D.  Correlation of MIC with outcome for Candida species tested against voriconazole: analysis and proposal for interpretive breakpoints..  Journal of clinical microbiology.  2006 March. 44(3):819-26.
[PubMed]

Polgreen P, Beekmann S, Chen Y, Doern G, Pfaller M, Brueggemann A, Herwaldt L, Diekema D.  Epidemiology of methicillin-resistant Staphylococcus aureus and vancomycin-resistant Enterococcus in a rural state..  Infection control and hospital epidemiology : the official journal of the Society of Hospital Epidemiologists of America.  2006 March. 27(3):252-6.
[PubMed]

Pfaller M, Boyken L, Hollis R, Messer S, Tendolkar S, Diekema D.  In vitro susceptibilities of Candida spp. to caspofungin: four years of global surveillance..  Journal of clinical microbiology.  2006 March. 44(3):760-3.
[PubMed]

Messer S, Diekema D, Boyken L, Tendolkar S, Hollis R, Pfaller M.  Activities of micafungin against 315 invasive clinical isolates of fluconazole-resistant Candida spp..  Journal of clinical microbiology.  2006 February. 44(2):324-6.
[PubMed]

Herwaldt L, Latenser B, Wibbenmeyer L, Coffman S, Winokur P, Diekema D.  "Miliary" infections caused by community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA) in a Burn Center.  2006. 

Diekema D, Boyken L, Hollis R, Kroeger J, Messer S, Tendolkar S, Pfaller M.  Anidulafungin activity against invasive clinical isolates of Candida: Relationship to fluconazole susceptibility.  2006. 

Ernst E, Ngo N, Miller J, Klevay M, Jepson R, Pfaller M, Diekema D.  Antimicrobial usage in C. glabrata and C. albicans bloodstream infection.  2006. 

Diekema D, Messer S, Boyken L, Tendolkar S, Kroeger J, Hollis R, Pfaller M.  Candida glabrata: Five years of sentinel antifungal resistance surveillance.  2006. 

Pfaller M, Diekema D, Mendez M, Kibbler C, Erzsebet P, Chang S, Gibbs D, Newell V.  Candida guilliermondii, an opportunistic fungal pathogen with decreased susceptibility to fluconazole: Global surveillance from the ARTEMIS disk antifungal surveillance program.  2006. 

Kuntz J, Herwaldt L, Applegate D, Ward M, Chen Y, Diekema D, Polgreen P.  Clostridium difficile associated disease among patients in a small rural hospital.  2006. 

Messer S, Diekema D, Hollis R, Boyken L, Tendolkar S, Kroeger J, Pfaller M.  Evaluation of disk diffusion and Etest compared to broth microdilution antifungal susceptibility testing of posaconazole against clinical isolates of filamentous fungi.  2006. 

Diekema D, Messer S, Hollis R, Boyken L, Tendolkar S, Kroeger J, Pfaller M.  Evaluation of Etest and disk diffusion methods compared to broth microdilution antifungal susceptibility testing of posaconazole against clinical isolates of Candida.  2006. 

Pfaller M, Boyken L, Hollis R, Messer S, Tendolkar S, Diekema D.  Global Surveillance of the in vitro activity of micafungin against Candida: A comparison with caspofungin using Clinical and Laboratory Standards Institute recommended methods.  2006. 

Diekema D, Messer S, Boyken L, Hollis R, Tendolkar S, Kroeger J, Pfaller M.  In vitro activity of caspofungin against rare Candida species.  2006. 

Diekema D, Pfaller M.  Infection control epidemiology and clinical microbiology.  2006. 

Herwaldt L, Schultz-Stubner S, Kuntz J, Diekema D.  Infection control practices among anesthesia providers (APs) in the 7 CDC prevention epicenter hospitals.  2006. 

Ernst E, Miller J, Jepson R, Klevay M, Pfaller M, Diekema D.  Risk factors for Candida glabrata bloodstream infection: A case-control study.  2006. 

Polgreen P, Diekema D, Applegate D, Chen Y, Killgore G, Kuntz J, Messer S, Thompson A, Vande Berg J, Herwaldt L.  Risk factors for Clostridium difficile associated disease (CDAD) at a Midwestern teaching hospital.  2006. 

Herwaldt L, Applegate D, Kuntz J, Ward M, Vande Berg J, Wibbenmeyer L, Diekema D.  Risk factors for colonization with MRSA or VRE on a Burn and Wound Unit.  2006. 

Huang S, Diekema D, Warren D, Zuccotti G, Winokur P, Tendolkar S, Boyken L, Datta R, Jones R, Ward M, Aubrey T, Onderdonk A, Platt R.  Strain relatedness of isolates from patients with serial methicillin-resistant Staphylococcus aureus infection.  2006. 

Polgreen P, Pottinger J, Polgreen L, Diekema D, Herwaldt L.  Influenza vaccination rates, feedback and the Hawthorne effect..  Infection control and hospital epidemiology : the official journal of the Society of Hospital Epidemiologists of America.  2006 January. 27(1):98-9.
[PubMed]

Polgreen P, Diekema D, Vandeberg J, Wiblin R, Chen Y, David S, Rasmus D, Gerdts N, Ross A, Katz L, Herwaldt L.  Risk factors for groin wound infection after femoral artery catheterization: a case-control study..  Infection control and hospital epidemiology : the official journal of the Society of Hospital Epidemiologists of America.  2006 January. 27(1):34-7.
[PubMed]

Pfaller M, Diekema D, Rinaldi M, Barnes R, Hu B, Veselov A, Tiraboschi N, Nagy E, Gibbs D.  Results from the ARTEMIS DISK Global Antifungal Surveillance Study: a 6.5-year analysis of susceptibilities of Candida and other yeast species to fluconazole and voriconazole by standardized disk diffusion testing..  Journal of clinical microbiology.  2005 December. 43(12):5848-59.
[PubMed]

Pfaller M, Diekema D, Boyken L, Messer S, Tendolkar S, Hollis R, Goldstein B.  Effectiveness of anidulafungin in eradicating Candida species in invasive candidiasis..  Antimicrobial agents and chemotherapy.  2005 November. 49(11):4795-7.
[PubMed]

Pfaller M, Boyken L, Hollis R, Messer S, Tendolkar S, Diekema D.  In vitro activities of anidulafungin against more than 2,500 clinical isolates of Candida spp., including 315 isolates resistant to fluconazole..  Journal of clinical microbiology.  2005 November. 43(11):5425-7.
[PubMed]

Pfaller M, Boyken L, Messer S, Tendolkar S, Hollis R, Diekema D.  Comparison of results of voriconazole disk diffusion testing for Candida species with results from a central reference laboratory in the ARTEMIS global antifungal surveillance program..  Journal of clinical microbiology.  2005 October. 43(10):5208-13.
[PubMed]

Pfaller M, Boyken L, Hollis R, Messer S, Tendolkar S, Diekema D.  In vitro susceptibilities of clinical isolates of Candida species, Cryptococcus neoformans, and Aspergillus species to itraconazole: global survey of 9,359 isolates tested by clinical and laboratory standards institute broth microdilution methods..  Journal of clinical microbiology.  2005 August. 43(8):3807-10.
[PubMed]

Sohn S, Climo M, Diekema D, Fraser V, Herwaldt L, Marino S, Noskin G, Perl T, Song X, Tokars J, Warren D, Wong E, Yokoe D, Zembower T, Sepkowitz K.  Varying rates of Clostridium difficile-associated diarrhea at prevention epicenter hospitals..  Infection control and hospital epidemiology : the official journal of the Society of Hospital Epidemiologists of America.  2005 August. 26(8):676-9.
[PubMed]

Klevay M, Ebinger A, Diekema D, Messer S, Hollis R, Pfaller M.  Disk diffusion testing using Candida sp. colonies taken directly from CHROMagar Candida medium may decrease time required to obtain results..  Journal of clinical microbiology.  2005 July. 43(7):3497-9.
[PubMed]

Ernst E, Raley G, Herwaldt L, Diekema D.  Importance of control group selection for evaluating antimicrobial use as a risk factor for methicillin-resistant Staphylococcus aureus bacteremia..  Infection control and hospital epidemiology : the official journal of the Society of Hospital Epidemiologists of America.  2005 July. 26(7):634-7.
[PubMed]

Beekmann S, Diekema D, Doern G.  Determining the clinical significance of coagulase-negative staphylococci isolated from blood cultures..  Infection control and hospital epidemiology : the official journal of the Society of Hospital Epidemiologists of America.  2005 June. 26(6):559-66.
[PubMed]

Richter S, Galask R, Messer S, Hollis R, Diekema D, Pfaller M.  Antifungal susceptibilities of Candida species causing vulvovaginitis and epidemiology of recurrent cases..  Journal of clinical microbiology.  2005 May. 43(5):2155-62.
[PubMed]

Pfaller M, Messer S, Boyken L, Rice C, Tendolkar S, Hollis R, Doern G, Diekema D.  Global trends in the antifungal susceptibility of Cryptococcus neoformans (1990 to 2004)..  Journal of clinical microbiology.  2005 May. 43(5):2163-7.
[PubMed]

Pfaller M, Diekema D.  Unusual fungal and pseudofungal infections of humans..  Journal of clinical microbiology.  2005 April. 43(4):1495-504.
[PubMed]

Diekema D, Messer S, Boyken L, Tendolkar S, Hollis R, Pfaller M.  Activity of New and Investigational Antifungal Agents against Recent Clinical Isolates of Filamentous Fungi.  2005. 

Diekema D, Messer S, Boyken L, Tendolkar S, Hollis R, Pfaller M.  Activity of New and Investigational Antifungal Agents against Recent Clinical Isolates of Filamentous Fungi.  2005. 

Polgreen P, Chen Y, Ward M, Coffman S, Diekema D, Hornick D, Herwaldt L.  An outbreak of C. difficile-associated diarrhea among elderly patients in a small rural hospital.  2005. 

Wilson D, Sutherland J, Diekema D.  Characteristics and outcomes of US hospitals that perform active surveillance for methicillin-resistant Staphylococcus aureus.  2005. 

Wilson D, Sutherland J, Diekema D.  Characteristics and outcomes of US hospitals that perform active surveillance for methicillin-resistant Staphylococcus aureus: Results of a large, national survey.  2005. 

Miller R, Park B, Fridkin S, Morrison V, Pappas P, Alexander B, Schuster M, Diekema D.  Characterization of very late onset invasive aspergillosis (IA) among organ transplant recipients.  2005. 

Miller R, Park B, Fridkin S, Morrison V, Pappas P, Alexander B, Schuster M, Diekema D.  Characterization of very late onset invasive aspergillosis (IA) among organ transplant recipients.  2005. 

Pfaller M, Boyken L, Messer S, Tendolkar S, Hollis R, Diekema D.  Comparison of Results of Voriconazole Disk Diffusion Testing for Candida Species with Results from a Central Reference Laboratory in the ARTEMIS Global Antifungal Surveillance Program.  2005. 

Pfaller M, Boyken L, Messer S, Tendolkar S, Hollis R, Diekema D.  Comparison of Results of Voriconazole Disk Diffusion Testing for Candida Species with Results from a Central Reference Laboratory in the ARTEMIS Global Antifungal Surveillance Program.  2005. 

Cosgrove S, Srinivasan A, Seo S, Bolon M, Climo M, Diekema D, Speck K, Gase K, Moskin G, Herwaldt L, Wong E, Song X, Curtis A, Solomon S, Tokars J, Perl T.  Evaluation of post-prescription review as a model of promoting rational antimicrobial use: A multi-center study.  2005. 

Messer S, Diekema D, Boyken L, Tendolkar S, Hollis R, Pfaller M.  Evaluation of the CLSI M44-A Disk Diffusion Method for Determining Susceptibilities of 584 Clinical Isolates of Cryptococcus neoformans to Voriconazole.  2005. 

Messer S, Diekema D, Boyken L, Tendolkar S, Hollis R, Pfaller M.  Evaluation of the CLSI M44-A Disk Diffusion Method for Determining Susceptibilities of 584 Clinical Isolates of Cryptococcus neoformans to Voriconazole.  2005. 

Alvis B, Diekema D, Messer S, Boyken L, Tendolkar S.  Evaluation of the Disk Diffusion Method Compared to Broth Microdilution Antifungal Susceptibility Testing of Voriconazole against Clinical Isolates of Filamentous Fungi.  2005. 

Alvis B, Diekema D, Messer S, Boyken L, Tendolkar S, Pfaller M.  Evaluation of the Disk Diffusion Method Compared to Broth Microdilution Antifungal Susceptibility Testing of Voriconazole against Clinical Isolates of Filamentous Fungi.  2005. 

Diekema D, Messer S, Boyken L, Tendolkar S, Hollis R, Pfaller M.  In vitro Activity of Caspofungin against Invasive Clinical Isolates of Candida: Four Years of Sentinel Surveillance.  2005. 

Diekema D, Messer S, Boyken L, Tendolkar S, Hollis R, Pfaller M.  In vitro Activity of Caspofungin against Invasive Clinical Isolates of Candida: Four Years of Sentinel Surveillance.  2005. 

Messer S, Diekema D, Boyken L, Tendolkar S, Hollis R, Pfaller M.  Micafungin Activity against 315 Invasive Clinical Isolates of Fluconazole Resistant Candida.  2005. 

Messer S, Diekema D, Boyken L, Tendolkar S, Hollis R, Pfaller M.  Micafungin Activity against 315 Invasive Clinical Isolates of Fluconazole Resistant Candida.  2005. 

Ince D, Winokur P, Beekmann S, Herwaldt L, Pfaller M, Doern G, Diekema D.  Prevalence of Panton Valentine Leukocidin genes among methicillin-resistant Staphylococcus aureus in Iowa.  2005. 

Diekema D, Messer S, Boyken L, Tendolkar S, Hollis R, Pfaller M.  Prospective Global Surveillance for Candida spp. Infection: Four Year Results from the ARTEMIS Study.  2005. 

Diekema D, Messer S, Boyken L, Tendolkar S, Hollis R, Pfaller M.  Prospective Global Surveillance for Candida spp. Infection: Four Year Results from the ARTEMIS Study.  2005. 

Polgreen P, Diekema D, Herwaldt L, Cavanaugh J, Nelson F, Neumann G.  The use of a prediction market to forecast influenza activity.  2005. 

Polgreen P, Diekema D, Herwaldt L, Cavanaugh J, Nelson F.  The use of a prediction market to forecast influenza activity.  2005. 

Diekema D, Petroelje B, Messer S, Hollis R, Pfaller M.  Activities of available and investigational antifungal agents against rhodotorula species..  Journal of clinical microbiology.  2005 January. 43(1):476-8.
[PubMed]

Ward M, Diekema D, Yankey J, Vaughn T, BootsMiller B, Pendergast J, Doebbeling B.  Implementation of strategies to prevent and control the emergence and spread of antimicrobial-resistant microorganisms in U.S. hospitals..  Infection control and hospital epidemiology : the official journal of the Society of Hospital Epidemiologists of America.  2005 January. 26(1):21-30.
[PubMed]

Flach S, Diekema D, Yankey J, BootsMiller B, Vaughn T, Ernst E, Ward M, Doebbeling B.  Variation in the use of procedures to monitor antimicrobial resistance in U.S. hospitals..  Infection control and hospital epidemiology : the official journal of the Society of Hospital Epidemiologists of America.  2005 January. 26(1):31-8.
[PubMed]

Yokoe D, Noskin G, Cunnigham S, Zuccotti G, Plaskett T, Fraser V, Olsen M, Tokars J, Solomon S, Perl T, Cosgrove S, Tilson R, Greenbaum M, Hooper D, Sands K, Tully J, Herwaldt L, Diekema D, Wong E, Climo M, Platt R.  Enhanced identification of postoperative infections among inpatients..  Emerging infectious diseases.  2004 November. 10(11):1924-30.
[PubMed]

Pfaller M, Boyken L, Messer S, Tendolkar S, Hollis R, Diekema D.  Evaluation of the etest method using Mueller-Hinton agar with glucose and methylene blue for determining amphotericin B MICs for 4,936 clinical isolates of Candida species..  Journal of clinical microbiology.  2004 November. 42(11):4977-9.
[PubMed]

Pfaller M, Boyken L, Hollis R, Messer S, Tendolkar S, Diekema D.  Clinical evaluation of a dried commercially prepared microdilution panel for antifungal susceptibility testing of five antifungal agents against Candida spp. and Cryptococcus neoformans..  Diagnostic microbiology and infectious disease.  2004 October. 50(2):113-7.
[PubMed]

Pfaller M, Diekema D.  Rare and emerging opportunistic fungal pathogens: concern for resistance beyond Candida albicans and Aspergillus fumigatus..  Journal of clinical microbiology.  2004 October. 42(10):4419-31.
[PubMed]

Pfaller M, Hazen K, Messer S, Boyken L, Tendolkar S, Hollis R, Diekema D.  Comparison of results of fluconazole disk diffusion testing for Candida species with results from a central reference laboratory in the ARTEMIS global antifungal surveillance program..  Journal of clinical microbiology.  2004 August. 42(8):3607-12.
[PubMed]

Siwek G, Dodgson K, de Magalhaes-Silverman M, Bartelt L, Kilborn S, Hoth P, Diekema D, Pfaller M.  Invasive zygomycosis in hematopoietic stem cell transplant recipients receiving voriconazole prophylaxis..  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.  2004 August. 39(4):584-7.
[PubMed]

Diekema D, Pfaller M.  Nosocomial candidemia: an ounce of prevention is better than a pound of cure..  Infection control and hospital epidemiology : the official journal of the Society of Hospital Epidemiologists of America.  2004 August. 25(8):624-6.
[PubMed]

Pfaller M, Messer S, Boyken L, Rice C, Tendolkar S, Hollis R, Diekema D.  Cross-resistance between fluconazole and ravuconazole and the use of fluconazole as a surrogate marker to predict susceptibility and resistance to ravuconazole among 12,796 clinical isolates of Candida spp..  Journal of clinical microbiology.  2004 July. 42(7):3137-41.
[PubMed]

Pfaller M, Messer S, Boyken L, Rice C, Tendolkar S, Hollis R, Diekema D.  Further standardization of broth microdilution methodology for in vitro susceptibility testing of caspofungin against Candida species by use of an international collection of more than 3,000 clinical isolates..  Journal of clinical microbiology.  2004 July. 42(7):3117-9.
[PubMed]

Pfaller M, Messer S, Boyken L, Tendolkar S, Hollis R, Diekema D.  Geographic variation in the susceptibilities of invasive isolates of Candida glabrata to seven systemically active antifungal agents: a global assessment from the ARTEMIS Antifungal Surveillance Program conducted in 2001 and 2002..  Journal of clinical microbiology.  2004 July. 42(7):3142-6.
[PubMed]

Diekema D, Dodgson K, Sigurdardottir B, Pfaller M.  Rapid detection of antimicrobial-resistant organism carriage: an unmet clinical need..  Journal of clinical microbiology.  2004 July. 42(7):2879-83.
[PubMed]

Ernst E, Diekema D, BootsMiller B, Vaughn T, Yankey J, Flach S, Ward M, Franciscus C, Acosta E, Pfaller M, Doebbeling B.  Are United States hospitals following national guidelines for the analysis and presentation of cumulative antimicrobial susceptibility data?.  Diagnostic microbiology and infectious disease.  2004 June. 49(2):141-5.
[PubMed]

Diekema D, Lee K, Raney P, Herwaldt L, Doern G, Tenover F.  Accuracy and appropriateness of antimicrobial susceptibility test reporting for bacteria isolated from blood cultures..  Journal of clinical microbiology.  2004 May. 42(5):2258-60.
[PubMed]

Polgreen P, Fultz S, Justice A, Wagner J, Diekema D, Rabeneck L, Weissman S, Stapleton J.  Association of hypocholesterolaemia with hepatitis C virus infection in HIV-infected people..  HIV medicine.  2004 May. 5(3):144-50.
[PubMed]

Pfaller M, Messer S, Boyken L, Hollis R, Rice C, Tendolkar S, Diekema D.  In vitro activities of voriconazole, posaconazole, and fluconazole against 4,169 clinical isolates of Candida spp. and Cryptococcus neoformans collected during 2001 and 2002 in the ARTEMIS global antifungal surveillance program..  Diagnostic microbiology and infectious disease.  2004 March. 48(3):201-5.
[PubMed]

Pfaller M, Boyken L, Messer S, Hollis R, Diekema D.  Stability of Mueller-Hinton agar supplemented with glucose and methylene blue for disk diffusion testing of fluconazole and voriconazole..  Journal of clinical microbiology.  2004 March. 42(3):1288-9.
[PubMed]

Pfaller M, Diekema D.  Twelve years of fluconazole in clinical practice: global trends in species distribution and fluconazole susceptibility of bloodstream isolates of Candida..  Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.  2004 March. 10 Suppl 1:11-23.
[PubMed]

Pfaller M, Diekema D, Messer S, Boyken L, Hollis R, Jones R.  In vitro susceptibilities of rare Candida bloodstream isolates to ravuconazole and three comparative antifungal agents..  Diagnostic microbiology and infectious disease.  2004 February. 48(2):101-5.
[PubMed]

Pfaller M, Hazen K, Messer S, Boyken L, Tendolkar S, Hollis R, Diekema D.  Accuracy of Fluconazole Disk Testing for Candida Species: Comparison of participant results with results from a central reference laboratory in the ARTEMIS Global Antifungal Surveillance Program.  2004. 

Diekema D, Petroelje B, Messer S, Hollis R, Pfaller M.  Activity of available and investigational antifungal agents against Rhodotorula species.  2004. 

Pfaller M, Pujol C, Diekema D, Messer S, Hollis R, Soll D.  Animal isolates of Candida albicans are not a source of resistance to common antifungal agents.  2004. 

Pfaller M, Boyken L, Messer S, Tendolkar S, Hollis R, Diekema D.  Clinical evaluation of a dried commercially prepared microdilution panel for antifungal susceptibility testing of Candida spp. and Cryptococcus neoformans.  2004. 

Pfaller M, Richter S, Diekema D.  Conventional methods for the laboratory diagnosis of fungal infections in the immunocompromised host.  2004. 

Klevay M, Ebinger A, Diekema D, Messer S, Hollis R, Pfaller M.  Disk diffusion testing of Candida inoculated directly from CHROMagar Candida medium may decrease time to results reporting.  2004. 

Sigurdardottir B, Dodgson K, Coffman S, Howard W, Vande Berg J, Doern G, Pfaller M, Herwaldt L, Diekema D.  Effect of real-time PCR detection of vancomycin-resistant enterococci (VRE) on time to detection of colonized patients.  2004. 

Pfaller M, Boyken L, Messer S, Tendolkar S, Hollis R, Diekema D.  Evaluation of the Etest method using Mueller-Hinton agar with glucose and methylene blue for determining amphotericin B MICs for Candida species.  2004. 

Dodgson K, Stence A, Diekema D, Pfaller M, Doern G.  Implementation of a real-time PCR assay for VRE directly from peri-rectal swabs.  2004. 

Polgreen P, Pottinger J, Diekema D, Person C, Coffman S, Hartley P, Herwaldt L.  Influenza vaccination rates and the Hawthorne Effect: Increasing healthcare worker vaccination rates using "half-time" appraisals and targeted interventions including performance feedback.  2004. 

Polgreen P, Diekema D, Herwaldt L, Neumann G, Nelson F.  Institutional factors associated with a novel antimicrobial resistance index.  2004. 

Wilson D, Yankey J, Vaughn T, Diekema D, Flach S, Ward M, Doebbeling B.  Institutional factors associated with a novel antimicrobial resistance index.  2004. 

Warren D, Christian L, Osa-Edoh O, Climo C, Wong E, Cunningham S, Noskin G, Zuccotti G, Plaskett T, Tokars J, Solomon S, Cosgrove S, Perl T, Yokoe D, Diekema D, Herwaldt L, Fraser V.  The impact of an educational intervention on healthcare worker knowledge of catheter-associated bloodstream infections.  2004. 

Beekmann S, Diekema D, Chapin K, Doern G.  The optimal algorithm for determining the clinical significance of coagulase-negative Staphylococci (CNS) and other common skin contaminants (CSC).  2004. 

Sohn S, Climo M, Diekema D, Fraser V, Herwaldt L, Marino S, Noskin G, Perl T, Song X, Tokars J, Warren D, Wong E, Yokoe D, Zembower T, Sepkowitz K.  Varying rates of Clostridium difficile diarrhea at Prevention Epicenter hospitals.  2004. 

Diekema D, BootsMiller B, Vaughn T, Woolson R, Yankey J, Ernst E, Flach S, Ward M, Franciscus C, Pfaller M, Doebbeling B.  Antimicrobial resistance trends and outbreak frequency in United States hospitals..  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.  2004 January. 38(1):78-85.
[PubMed]

Pfaller M, Messer S, Boyken L, Rice C, Tendolkar S, Hollis R, Diekema D.  Evaluation of the NCCLS M44-P disk diffusion method for determining susceptibilities of 276 clinical isolates of Cryptococcus neoformans to fluconazole..  Journal of clinical microbiology.  2004 January. 42(1):380-3.
[PubMed]

Pfaller M, Messer S, Boyken L, Rice C, Tendolkar S, Hollis R, Diekema D.  Caspofungin activity against clinical isolates of fluconazole-resistant Candida..  Journal of clinical microbiology.  2003 December. 41(12):5729-31.
[PubMed]

Climo M, Diekema D, Warren D, Herwaldt L, Perl T, Peterson L, Plaskett T, Price C, Sepkowitz K, Solomon S, Tokars J, Fraser V, Wong E.  Prevalence of the use of central venous access devices within and outside of the intensive care unit: results of a survey among hospitals in the prevention epicenter program of the Centers for Disease Control and Prevention..  Infection control and hospital epidemiology : the official journal of the Society of Hospital Epidemiologists of America.  2003 December. 24(12):942-5.
[PubMed]

Gudlaugsson O, Gillespie S, Lee K, Vande Berg J, Hu J, Messer S, Herwaldt L, Pfaller M, Diekema D.  Attributable mortality of nosocomial candidemia, revisited..  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.  2003 November. 37(9):1172-7.
[PubMed]

Diekema D.  Use of active surveillance cultures to control vancomycin-resistant Enterococcus..  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.  2003 November. 37(10):1400-2; author reply 1402-3.
[PubMed]

Diekema D, Messer S, Hollis R, Jones R, Pfaller M.  Activities of caspofungin, itraconazole, posaconazole, ravuconazole, voriconazole, and amphotericin B against 448 recent clinical isolates of filamentous fungi..  Journal of clinical microbiology.  2003 August. 41(8):3623-6.
[PubMed]

Diekema D, Beekmann S, Chapin K, Morel K, Munson E, Doern G.  Epidemiology and outcome of nosocomial and community-onset bloodstream infection..  Journal of clinical microbiology.  2003 August. 41(8):3655-60.
[PubMed]

Beekmann S, Diekema D, Chapin K, Doern G.  Effects of rapid detection of bloodstream infections on length of hospitalization and hospital charges..  Journal of clinical microbiology.  2003 July. 41(7):3119-25.
[PubMed]

Diekema D.  Rapid response is best bet.  Washington Post.  2003 July. 

Diekema D, Andrews J, Huynh H, Rhomberg P, Doktor S, Beyer J, Shortridge V, Flamm R, Jones R, Pfaller M.  Molecular epidemiology of macrolide resistance in neonatal bloodstream isolates of group B streptococci..  Journal of clinical microbiology.  2003 June. 41(6):2659-61.
[PubMed]

Andrews J, Diekema D, Yankowitz J.  Prenatal testing for infectious disease..  Clinics in laboratory medicine.  2003 June. 23(2):295-315, viii.
[PubMed]

Pfaller M, Diekema D, Boyken L, Messer S, Tendolkar S, Hollis R.  Evaluation of the Etest and disk diffusion methods for determining susceptibilities of 235 bloodstream isolates of Candida glabrata to fluconazole and voriconazole..  Journal of clinical microbiology.  2003 May. 41(5):1875-80.
[PubMed]

Pfaller M, Messer S, Boyken L, Tendolkar S, Hollis R, Diekema D.  Variation in susceptibility of bloodstream isolates of Candida glabrata to fluconazole according to patient age and geographic location..  Journal of clinical microbiology.  2003 May. 41(5):2176-9.
[PubMed]

Pfaller M, Diekema D, Messer S, Boyken L, Hollis R.  Activities of fluconazole and voriconazole against 1,586 recent clinical isolates of Candida species determined by Broth microdilution, disk diffusion, and Etest methods: report from the ARTEMIS Global Antifungal Susceptibility Program, 2001..  Journal of clinical microbiology.  2003 April. 41(4):1440-6.
[PubMed]

Pfaller M, Messer S, Boyken L, Hollis R, Diekema D.  In vitro susceptibility testing of filamentous fungi: comparison of Etest and reference M38-A microdilution methods for determining posaconazole MICs..  Diagnostic microbiology and infectious disease.  2003 April. 45(4):241-4.
[PubMed]

Maxwell M, Messer S, Hollis R, Boyken L, Tendolkar S, Diekema D, Pfaller M.  Evaluation of Etest method for determining fluconazole and voriconazole MICs for 279 clinical isolates of Candida species infrequently isolated from blood..  Journal of clinical microbiology.  2003 March. 41(3):1087-90.
[PubMed]

Klepser M, Klepser D, Ernst E, Brooks J, Diekema D, Mozaffari E, Hendrickson J, Doern G.  Health care resource utilization associated with treatment of penicillin-susceptible and -nonsusceptible isolates of Streptococcus pneumoniae..  Pharmacotherapy.  2003 March. 23(3):349-59.
[PubMed]

Pfaller M, Diekema D, Messer S, Hollis R, Jones R.  In vitro activities of caspofungin compared with those of fluconazole and itraconazole against 3,959 clinical isolates of Candida spp., including 157 fluconazole-resistant isolates..  Antimicrobial agents and chemotherapy.  2003 March. 47(3):1068-71.
[PubMed]

Pfaller J, Messer S, Hollis R, Diekema D, Pfaller M.  In vitro susceptibility testing of Aspergillus spp.: comparison of Etest and reference microdilution methods for determining voriconazole and itraconazole MICs..  Journal of clinical microbiology.  2003 March. 41(3):1126-9.
[PubMed]

Richter S, Diekema D, Heilmann K, Almer L, Shortridge V, Zeitler R, Flamm R, Doern G.  Fluoroquinolone resistance in Streptococcus pyogenes..  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.  2003 February. 36(3):380-3.
[PubMed]

Warren D, Osa-Edoh O, Climo M, Wong E, Cunningham S, Noskin G, Zuccotti G, Plaskett T, Tokars J, Solomon S, Cosgrove S, Perl T, Diekema D, Herwaldt L, Fraser V.  A multicenter intervention to prevent catheter-associated bloodstream infections in the ICU.  2003. 

Pfaller M, Messer S, Boyken L, Hollis R, Rice C, Tendolkar S, Diekema D.  Activities of voriconazole, posaconazole and fluconazole against 3,932 Candida species and 237 Cryptococcus neoformans: Report from the ARTEMIS Global Antifungal Surveillance Program, 2001-2002.  2003. 

Diekema D, BootsMiller B, Ernst E, Flach S, Franciscus C, Pfaller M, Vaughn T, Ward M, Woolson R, Yankey J, Doebbeling B.  Antimicrobial Resistance (AMR) Trends and Outbreak Frequency in United States Hospitals: Nationwide Surveys of Infection Control Professionals (ICPs) and Laboratory Directors (LDs).  2003. 

Doebbeling B, Diekema D, Vaughn T, Yankey J, BootsMiller B, Flach S, Ernst E, Ward M, Franciscus C, Acosta E, Pfaller M.  Are US Hospitals following Antimicrobial Resistance Prevention and Control Guidelines?.  2003. 

Ernst E, Yankey J, Diekema D, Pfaller M, BootsMiller B, Vaughn T, Ward M, Flach S, Franciscus C, Acotsa E, Doebbeling B.  Are US Hospitals following National Guidelines for the Analysis and Presentation of Antibiogram Data?.  2003. 

Sigurdardottir B, Diekema D, Gillespie S, Johnson E, Vande Berg J, Herwaldt L.  Descriptive epidemiology of patients co-colonized with vancomycin-resistant Enterococcus spp. and methicillin-resistant Staphylococcus aureus.  2003. 

Yankey J, Diekema D, Vaughn T, Ernst E, BootsMiller B, Flach S, Ward M, Pendergast J, Doebbeling B.  Development and validation of a novel index to compare antimicrobial resistance across types of hospitals.  2003. 

Pfaller M, Messer S, Boyken L, Hollis R, Rice C, Tendolkar S, Diekema D.  Evaluation of the NCCLS M44-P disk diffusion method for determining the fluconazole susceptibility of 276 clinical isolates of Cryptococcus neoformans.  2003. 

Flach S, Yankey J, Diekema D, Vaughn T, BootsMiller B, Ward M, Ernst E, Doebbeling B.  Hospitals' Use of Laboratory Procedures to Control Antimicrobial Resistance.  2003. 

Pfaller M, Hollis R, Goldstein B, Messer S, Diekema D, Henkel T.  In Vitro activity of anidulafungin and other agents against 526 esophageal candidiasis isolates.  2003. 

Pfaller M, Diekema D, Messer S, Boyken L, Hollis R, Jones R.  In vitro susceptibilities of bloodstream isolates of rare Candida species against ravuconazole and three licensed antifungal agents.  2003. 

Beekmann S, Heilmann K, Sauter C, Diekema D, Doern G.  Methicillin-resistant S. aureus in Long-Term Care Facilities: Results from a Nationwide Surveillance Study.  2003. 

Diekema D, Pfaller M.  New antigungal agents.  Infections in Medicine.  2003. 20:2-2.

Shamsuddin H, Diekema D.  Opportunistic infections in hematopoetic transplant recipients.  2003. 

Andrew J, Diekema D, Yankowitz J.  Prenatal testing for infectious diseases.  Clin Lab Med.  2003. 4:1-21.

Diekema D.  The clinician and the microbiology laboratory.  2003. 

Ernst E, Raley G, Herwaldt L, Hu J, Vandeberg J, Diekema D.  The Importance of Control Group Selection for Evaluating Antimicrobial Usage as a Risk Factor for Methicillin-Resistant Staphylococcus aureus Bacteremia.  2003. 

Munson E, Diekema D, Beekmann S, Chapin K, Doern G.  Detection and treatment of bloodstream infection: laboratory reporting and antimicrobial management..  Journal of clinical microbiology.  2003 January. 41(1):495-7.
[PubMed]

Maxwell M, Messer S, Hollis R, Diekema D, Pfaller M.  Evaluation of Etest method for determining voriconazole and amphotericin B MICs for 162 clinical isolates of Cryptococcus neoformans..  Journal of clinical microbiology.  2003 January. 41(1):97-9.
[PubMed]

Pfaller M, Diekema D, Messer S, Boyken L, Hollis R, Jones R.  In vitro activities of voriconazole, posaconazole, and four licensed systemic antifungal agents against Candida species infrequently isolated from blood..  Journal of clinical microbiology.  2003 January. 41(1):78-83.
[PubMed]

Diekema D.  Smallpox vaccinations.  New York Times.  2003 January. 

Diekema D, Pfaller M, Jones R.  Age-related trends in pathogen frequency and antimicrobial susceptibility of bloodstream isolates in North America: SENTRY Antimicrobial Surveillance Program, 1997-2000..  International journal of antimicrobial agents.  2002 December. 20(6):412-8.
[PubMed]

Diekema D.  Alcohol-based hand gels and hand hygiene in hospitals..  Lancet.  2002 November. 360(9344):1510; author reply 1511.
[PubMed]

Pfaller M, Messer S, Boyken L, Huynh H, Hollis R, Diekema D.  In vitro activities of 5-fluorocytosine against 8,803 clinical isolates of Candida spp.: global assessment of primary resistance using National Committee for Clinical Laboratory Standards susceptibility testing methods..  Antimicrobial agents and chemotherapy.  2002 November. 46(11):3518-21.
[PubMed]

Pfaller M, Diekema D.  Role of sentinel surveillance of candidemia: trends in species distribution and antifungal susceptibility..  Journal of clinical microbiology.  2002 October. 40(10):3551-7.
[PubMed]

Richter S, Beekmann S, Croco J, Diekema D, Koontz F, Pfaller M, Doern G.  Minimizing the workup of blood culture contaminants: implementation and evaluation of a laboratory-based algorithm..  Journal of clinical microbiology.  2002 July. 40(7):2437-44.
[PubMed]

Pfaller M, Messer S, Hollis R, Jones R, Diekema D.  In vitro activities of ravuconazole and voriconazole compared with those of four approved systemic antifungal agents against 6,970 clinical isolates of Candida spp..  Antimicrobial agents and chemotherapy.  2002 June. 46(6):1723-7.
[PubMed]

Pfaller M, Diekema D, Messer S, Boyken L, Huynh H, Hollis R.  Clinical evaluation of a frozen commercially prepared microdilution panel for antifungal susceptibility testing of seven antifungal agents, including the new triazoles posaconazole, ravuconazole, and voriconazole..  Journal of clinical microbiology.  2002 May. 40(5):1694-7.
[PubMed]

Diekema D, Messer S, Brueggemann A, Coffman S, Doern G, Herwaldt L, Pfaller M.  Epidemiology of candidemia: 3-year results from the emerging infections and the epidemiology of Iowa organisms study..  Journal of clinical microbiology.  2002 April. 40(4):1298-302.
[PubMed]

Pfaller M, Diekema D, Jones R, Messer S, Hollis R.  Trends in antifungal susceptibility of Candida spp. isolated from pediatric and adult patients with bloodstream infections: SENTRY Antimicrobial Surveillance Program, 1997 to 2000..  Journal of clinical microbiology.  2002 March. 40(3):852-6.
[PubMed]

Lewis R, Diekema D, Messer S, Pfaller M, Klepser M.  Comparison of Etest, chequerboard dilution and time-kill studies for the detection of synergy or antagonism between antifungal agents tested against Candida species..  The Journal of antimicrobial chemotherapy.  2002 February. 49(2):345-51.
[PubMed]

Diekema D, Lee K, Raney P, Herwaldt L, Doern G, Tenover F.  Accuracy and appropriateness of antimicrobial susceptibility test reporting for bacteria isolated from blood cultures.  2002. 

Pfaller M, Diekema D, Messer S, Boyken L, Hollis R.  Activity of fluconazole and voriconazole determined by broth microdilution, disk diffusion and Etest methods against 1897 recent clinical isolates of Candida species: Report from the ARTEMIS Global Anfungal Susceptibility Program, 2001.  2002. 

Diekema D, Messer S, Hollis R, Jones R, Pfaller M.  Antifungal activity of caspofungin and the new triazoles compared with itraconazole and amphotericin B against 462 recent clinical isolates of Aspergillus and other filamentous fungi.  2002. 

Diekema D, BootsMiller B, Vaughn T, Ward M, Ernst E, Flach S, Nora J, Woolson R, Franciscus C, Acotsa E, Pfaller M, Doebbeling B.  Antimicrobial resistance trends and outbreak frequency in United States Hospitals.  2002. 

Maxwell M, Messer S, Hollis R, Diekema D, Pfaller M.  Evaluation of Etest method for determining voriconazole and amphotericin B minimum inhibitory concentrations for 162 clinical isolates of Cryptococcus neoformans.  2002. 

Diekema D, Messer S, Hollis R, Jones R, Pfaller M.  Five years of longitudinal global surveillance for Candida spp. infection: Stability of species distribution and fluconazole susceptibility from 1997-2001.  2002. 

Stapleton J, Diekema D, Xiang J.  GB virus C and mortality from HIV infection.  N Engl J Med.  2002. 346:377.

Pfaller M, Diekema D, Messer S, Hollis R, Jones R.  In vitro activities of caspofungin compared with those of fluconaozole and itraconazole against 3959 clinical isolates of Candida spp., including 157 fluconazole-resistant isolates.  2002. 

Pfaller M, Messer S, Boyken L, Huynh H, Hollis R, Diekema D.  In vitro activity of 5-flourocytosine (5-FC) against 6973 clinical isolates of Candida spp.: A global assessment of primary resistance using NCCLS susceptibility testing methods.  2002. 

Andrews J, Diekema D, Huynh H, Rhomberg P, Hollis R, Jones R, Pfaller M.  Molecular Epidemiology of Macrolide Resistance among Group B Streptococci: Association of Macrolide Resistance with a Common PFGE Type of Serotype V.  2002. 

Gudlaugsson O, Gillespie S, Lee K, Vande Berg J, Messer S, Herwaldt L, Pfaller M, Diekema D.  Nosocomial candidemia: Attributable mortality and excess length of stay revisited.  2002. 

Climo M, Diekema D, Fraser V, Hewaldt L, Perl T, Peterson L, Plaskett T, Price C, Sepkowitz K, Solomon S, Tokars J, Wong E.  Prevalence of central line use in and outside the intensive care unit: Results of a survey among hospitals in the CDC's Prevention Epicenter Program.  2002. 

Warren D, Osa-Edoh O, Tyakoe D, Sepkowitz K, Tokars J, Perl T, Gramatikova A, Platt R, Diekema D, Herwaldt L, Climo M, Wong E, Noskin G, Plaskett T, Solomon S, Fraser V.  Preventing catheter-associated bloodstream infections: A survey of policies for insertion and care of central venous catheters from multiple hospitals.  2002. 

Diekema D, Pfaller M.  Role of the clinical microbiology laboratory in hospital epidemiology and infection control.  2002. 

Diekema D, Messer S, Brueggemann A, Coffman S, Doern G, Herwaldt L, Pfaller M.  The epidemiology of candidemia: Three-year results from the Emerging Infections and the Epidemiology of Iowa Organisms study.  2002. 

Beekmann S, Diekema D, Munson E, Doern G.  The specificity and positive predictive value of the NNIS definition for laboratory confirmed bloodstream infection with common skin contaminants.  2002. 

Diekema D, Jones R.  Oxazolidinone antibiotics..  Lancet.  2001 December. 358(9297):1975-82.
[PubMed]

Yamazumi T, Furuta I, Diekema D, Pfaller M, Jones R.  Comparison of the Vitek gram-positive susceptibility 106 card, the MRSA-Screen latex agglutination test, and mecA analysis for detecting oxacillin resistance in a geographically diverse collection of clinical isolates of coagulase-negative staphylococci..  Journal of clinical microbiology.  2001 October. 39(10):3633-6.
[PubMed]

Xiang J, Wunschmann S, Diekema D, Klinzman D, Patrick K, George S, Stapleton J.  Effect of coinfection with GB virus C on survival among patients with HIV infection..  The New England journal of medicine.  2001 September. 345(10):707-14.
[PubMed]

Pfaller M, Diekema D, Jones R, Sader H, Fluit A, Hollis R, Messer S.  International surveillance of bloodstream infections due to Candida species: frequency of occurrence and in vitro susceptibilities to fluconazole, ravuconazole, and voriconazole of isolates collected from 1997 through 1999 in the SENTRY antimicrobial surveillance program..  Journal of clinical microbiology.  2001 September. 39(9):3254-9.
[PubMed]

Walsh T, Bolmstrom A, Qwarnstrom A, Ho P, Wootton M, Howe R, MacGowan A, Diekema D.  Evaluation of current methods for detection of staphylococci with reduced susceptibility to glycopeptides..  Journal of clinical microbiology.  2001 July. 39(7):2439-44.
[PubMed]

Hanberger H, Diekema D, Fluit A, Jones R, Struelens M, Spencer R, Wolff M.  Surveillance of antibiotic resistance in European ICUs..  The Journal of hospital infection.  2001 July. 48(3):161-76.
[PubMed]

Diekema D, Pfaller M, Schmitz F, Smayevsky J, Bell J, Jones R, Beach M.  Survey of infections due to Staphylococcus species: frequency of occurrence and antimicrobial susceptibility of isolates collected in the United States, Canada, Latin America, Europe, and the Western Pacific region for the SENTRY Antimicrobial Surveillance Program, 1997-1999..  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.  2001 May. 32 Suppl 2:S114-32.
[PubMed]

Diekema D, Beach M, Pfaller M, Jones R.  Antimicrobial resistance in viridans group streptococci among patients with and without the diagnosis of cancer in the USA, Canada and Latin America..  Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.  2001 March. 7(3):152-7.
[PubMed]

David S, Vandeberg J, Knapp C, Kuhns K, Boyken L, Erenberger C, Wiblin R, Diekema D, Herwaldt L.  A cluster of complicated groin wound infections after femoral artery catheterization.  2001. 

Nora J, Diekema D, Vaughn T, Ward M, Franciscus C, Bootsmiller B, Woolson R, Doebbeling B.  Antimicrobial resistance in epidemiologically important organisms in US hospitals.  2001. 

Diekema D, Franciscus C, Vaughn T, Ward M, Woolson R, Pfaller M, Bootsmiller B, Doebbeling B.  Clinical microbiology laboratory support for infection control and antimicrobial resistance control.  2001. 

Diekema D, Beekmann S, Chapin K, Doern G.  Epidemiology and outcome of bloodstream infection in the new millennium.  2001. 

Nora J, Diekema D, Vaughn T, Ward M, Franciscus C, Bootsmiller B, Woolson R, Doebbeling B.  Implementation of guidelines to control antimicrobial resistance in US hospitals.  2001. 

Richter S, Beekmann S, Croco J, Diekema D, Koontz F, Pfaller M, Doern G.  Minimizing the workup of blood culture contaminants: Implementation and evaluation of a laboratory based algorithm.  2001. 

Diekema D, Beach M, Pfaller M, Jones R.  Nosocomial Staphylococcus aureus bacteremia: A four year update from the SENTRY Antimicrobial Surveillance Program (US and Canada).  2001. 

Beekmann S, Diekema D, Chapin K, Doern G.  Patient outcomes and other factors related to rapid detection of bacteremia using a continuous monitoring blood culture system.  2001. 

Pfaller M, Jones R, Diekema D, Beach M.  Trends in antimicrobial susceptibility of bacterial pathogens isolated from patients with bloodstream infections in North America: SENTRY Program, 1997-2000.  2001. 

Yamazumi T, Marshall S, Wilke W, Diekema D, Pfaller M, Jones R.  Comparison of the Vitek Gram-Positive Susceptibility 106 card and the MRSA-screen latex agglutination test for determining oxacillin resistance in clinical bloodstream isolates of Staphylococcus aureus..  Journal of clinical microbiology.  2001 January. 39(1):53-6.
[PubMed]

Andrews J, Diekema D, Hunter S, Rhomberg P, Pfaller M, Jones R, Doern G.  Group B streptococci causing neonatal bloodstream infection: antimicrobial susceptibility and serotyping results from SENTRY centers in the Western Hemisphere..  American journal of obstetrics and gynecology.  2000 October. 183(4):859-62.
[PubMed]

Diekema D, Pfaller M, Jones R, Doern G, Kugler K, Beach M, Sader H.  Trends in antimicrobial susceptibility of bacterial pathogens isolated from patients with bloodstream infections in the USA, Canada and Latin America. SENTRY Participants Group..  International journal of antimicrobial agents.  2000 February. 13(4):257-71.
[PubMed]

Richter S, Diekema D, Beach M, Doern G, Jones R, Pfaller M.  Agreement between referring laboratory antimicrobial susceptibility test results with the central monitor laboratory when testing bloodstream isolates: SENRY Antimicrobial Resistance Surveillance Program.  2000. 

Diekema D, Pfaller M, Beach M, Doern G, Jones R.  Antimicrobial susceptibility of viridans group streptococci bloodstream isolates from cancer patients at SENTRY centers in the US, Canada, and Latin America.  2000. 

Diekema D, Brueggemann A, Doern G.  Antimicrobial-drug use and changes in resistance in Streptococcus pneumoniae..  Emerging infectious diseases.  2000. 6(5):552-6.
[PubMed]

Diekema D.  Drug Resistance.  2000. 

Beekmann S, Diekema D, Chapin K, Morel K, Doern G.  Effects of rapid detection of bacteremia using a continuous monitoring blood culture system on measures of patient outcome.  2000. 

Franciscus C, Vaughn T, Ward M, Diekema D, Woolson R.  Epidemiology and control of antimicrobial resistance in VA and non-VA hospitals.  2000. 

Beekmann S, Diekema D, Brueggemann A, Pfaller M, Jones R, Doern G, Herwaldt L.  Epidemiology of mecthicillin-resistant Staphylococcus aureus and prevalance of true community-acquired MRSA in an Iowa Statewide Surveillance Network.  2000. 

Klepser M, Klepser D, Brooks J, Ernst E, Diekema D, Hoffman H, Mozaffari E, Hkendrickson J, Doern G.  Examination of healthcare resource utilization associated with the treatment of infections caused by susceptible and non-susceptible isolates of Streptococcus pneumoniae.  2000. 

Diekema D, Pfaller M, Turnidge J, Verhoef J, Bell J, Fluit A, Doern G, Jones R.  Genetic relatedness of multidrug-resistant, methicillin (oxacillin)-resistant Staphylococcus aureus bloodstream isolates from SENTRY Antimicrobial Resistance Surveillance Centers worldwide, 1998..  Microbial drug resistance (Larchmont, N.Y.).  2000. 6(3):213-21.
[PubMed]

Andrews J, Diekema D, Coffman S, Pfaller M, Jones R, Doern G.  Group B Streptococci causing neonatal bloodstream infection: Antimicrobial susceptibility and serotyping results from SENTRY centers in the Western Hemisphere.  2000. 

Diekema D, Jones R.  Microbiology of infections in the coronary care unit.  Antibiotics for Clinicians.  2000. 4:5-10.

Diekema D, Jones R.  Microbiology of infections in the coronary care unit.  Antibiotics for Clinicians.  2000. 23:5-10.

Diekema D, Beekmann S, Brueggemann A, Herwaldt L, Pfaller M, Jones R, Doern G.  Molecular epidemiology of community-acquired oxacillin-resistant Staphylococcus aureus from the Emerging Infections and the Epidemiology of Iowa Organisms (EIEIO) Study.  2000. 

Diekema D, Pfaller M, Turnidge J, Bell J, Verhoef J, Fluit A, Beach M, Stillwell M, Jones R.  Oxacillin- and multiple-drug resistance among Staphylococcus aureus: Results of the SENTRY Antimicrobial Resistance Surveillance Program, 1997-1999.  2000. 

Diekema D, Jones R.  Oxazolidinones: a review..  Drugs.  2000 January. 59(1):7-16.
[PubMed]

Diekema D, Marchesseault A.  Clinical impact of changing to an automated blood-culture system at a small community hospital..  Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.  1999 September. 5(9):590-593.
[PubMed]

Deshpande L, Diekema D, Jones R.  Comparative activity of clinafloxacin and nine other compounds tested against 2000 contemporary clinical isolates from patients in United States hospitals..  Diagnostic microbiology and infectious disease.  1999 September. 35(1):81-8.
[PubMed]

Diekema D, Pfaller M, Messer S, Houston A, Hollis R, Doern G, Jones R.  In vitro activities of BMS-207147 against over 600 contemporary clinical bloodstream isolates of Candida species from the SENTRY Antimicrobial Surveillance Program in North America and Latin America..  Antimicrobial agents and chemotherapy.  1999 September. 43(9):2236-9.
[PubMed]

Diekema D, Pfaller M, Jones R, Doern G, Winokur P, Gales A, Sader H, Kugler K, Beach M.  Survey of bloodstream infections due to gram-negative bacilli: frequency of occurrence and antimicrobial susceptibility of isolates collected in the United States, Canada, and Latin America for the SENTRY Antimicrobial Surveillance Program, 1997..  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.  1999 September. 29(3):595-607.
[PubMed]

Diekema D, Jones R, Rolston K.  Antimicrobial activity of gatifloxacin compared to seven other compounds tested against gram-positive organisms isolated at 10 cancer-treatment centers..  Diagnostic microbiology and infectious disease.  1999 May. 34(1):37-43.
[PubMed]

Diekema D, Coffman S, Marshall S, Beach M, Rolston K, Jones R.  Comparison of activities of broad-spectrum beta-lactam compounds against 1,128 gram-positive cocci recently isolated in cancer treatment centers..  Antimicrobial agents and chemotherapy.  1999 April. 43(4):940-3.
[PubMed]

Pfaller M, Diekema D, Messer S, Houston A, Hollis R, Doern G, Jones R.  Antifungal activity of BMS-207147, a new triazole antifungal agent, tested against 613 bloodstream isolates of Candida spp. from the SENTRY Antimicrobial Surveillance Program in North America and Latin America.  1999. 

Diekema D, Jones R, Rolston K.  Antimicrobial activity of gatifloxacin compared to seven other compounds tested against gram-positive organisms isolated at 10 cancer-treatment centers.  1999. 

Diekema D, Jones R.  Antimicrobial activity of quinuprstin-dalfopristin against gram-positive bacteria: results from recent studies.  Infect Oncol.  1999. 3:6-9.

Diekema D, Marshall S, Deshpande L, Jones R.  Comparative activity update of clinafloxacin testing against 2,000 contemporary clinical isolates from patients in United States Hospitals.  1999. 

Lewis R, Diekema D, Messer S, faller M, Klepser M.  Comparison of Etest checkerboard dilution, and time-kill testing for the detection of synergy or antagonism among Candida spp.  1999. 

Pfaller M, Diekema D, Jones R, Doern G.  Frequency of occurrence and trends in antimicrobial susceptibility of bacterial pathogens isolated from patients with bloodstream infections in the United States, Canada, and Latin America: Report from the SENTRY Antimicrobial Surveillance Program.  1999. 

Diekema D, Pfaller M, Turnidge J, Verhoef J, Fluit A, Doern G, Jones R.  Genetic relatedness of multidrug-resistant, methicillin-resistant Staphylococcus aureus causing bloodstream infection at SENTRY centers on five continents during 1998.  1999. 

Diekema D, Brueggemann A, Doern G.  Relationship between outpatient antimicrobial usage in metropolitan areas and changes in resistance of Streptococcus pneumoniae at 23 hospitals in the United States.  1999. 

Diekema D, Pfaller M, Jones R, Doern G.  Survey of bloodstream infections due to gram-negative bacilli: Frequency of occurrence and antimicrobial susceptibility of isolates collected in the United States, Canada and Latin America for the SENTRY Antimicrobial Surveillance Program.  1999. 

Diekema D, Marchesseault A.  Clinical impact of a continuous-monitoring blood culture system at a small community hospital.  1998. 

Diekema D, Doebbeling B.  Employee health and infection control.  1998. 

Diekema D, Barr J, Boyken L, Buschelman B, Jones R, Pfaller M, Herwaldt L.  A cluster of serious Escherichia coli infections in a neonatal intensive-care unit..  Infection control and hospital epidemiology : the official journal of the Society of Hospital Epidemiologists of America.  1997 November. 18(11):774-6.
[PubMed]

Diekema D, Messer S, Hollis R, Wenzel R, Pfaller M.  An outbreak of Candida parapsilosis prosthetic valve endocarditis..  Diagnostic microbiology and infectious disease.  1997 November. 29(3):147-53.
[PubMed]

Diekema D, Albanese M, Densen P, Doebbeling B.  Student health policies of U.S. medical schools..  Academic medicine : journal of the Association of American Medical Colleges.  1996 October. 71(10):1090-2.
[PubMed]

Diekema D, Albanese M, Schuldt S, Doebbeling B.  Blood and body fluid exposures during clinical training: relation to knowledge of universal precautions..  Journal of general internal medicine.  1996 February. 11(2):109-11.
[PubMed]

Diekema D, Schuldt S, Albanese M, Doebbeling B.  Universal precautions training of preclinical students: impact on knowledge, attitudes, and compliance..  Preventive medicine.  1995 November. 24(6):580-5.
[PubMed]

Diekema D, Doebbeling B.  Employee health and infection control..  Infection control and hospital epidemiology : the official journal of the Society of Hospital Epidemiologists of America.  1995 May. 16(5):292-301.
[PubMed]

Diekema D, Messer S, Hollis R, Pfaller M, Wenzel R.  An outbreak of Candida parapsilosis prosthetic valve endocarditis.  1995. 

Diekema D, Albanese M, Densen P, Doebbeling B.  Protecting medical students from infection: A survey of United States medical schools.  1995. 

Diekema D, Ferguson K, Doebbeling B.  Motivation for hepatitis B vaccine acceptance among medical and physician assistant students..  Journal of general internal medicine.  1995 January. 10(1):1-6.
[PubMed]

Doebbeling B, Garvin M, Diekema D, Weismann D.  Evaluation of interventions to reduce percutaneous injuries in healthcare workers.  1994. 

Diekema D, Albanese M, Schulte S, Doebbeling B.  Long term impact of universal precautions training on knowledge, compliance, attitudes and exposures.  1994. 

Diekema D, Ferguson K, Doebbeling B.  Motivation for compliance with hepatitis B vaccination among medical student.  1994. 

Diekema D, Garvin M, Weismann D, Rasley D, Streed S, Doebbling B.  The impact of interventions to reduce sharps injuries: a decade of experience.  1994. 

Schuldt S, Diekema D, Albanese M, Doebbeling B.  Universal precautions training of preclinical students: Impact on knowledge, attitudes and behavior.  1994. 

Diekema D, Albanese M, Schulte S, Doebbeling B.  Universal precautions training of preclinical students: relationship of knowledge to exposure rates during clinical training.  1994. 

Philbrick J, Becker D, Ballew K, Buckley R, Diekema D, Koberna P.  Risk factors for stroke in nonrheumatic atrial fibrillation..  The American journal of medicine.  1992 June. 92(6):709-10.
[PubMed]

Pfaller M, Diekema D, Rinaldi M.  Antifungal drugs: Mechanisms of action, drug resistance, susceptibility testing, and assays of activity in biologic fluids. 

Date Last Modified: 06/07/2014 - 21:56:23